Technical University of Munich spin-out ImevaX partners with Project Pharmaceuticals on stomach pain.
ImevaX, a biotech spin-out of the Technical University of Munich, has announced plans to partner with Germany-based Project Pharmaceuticals on tackling stomach pain caused by bacterium.
Specifically, the two companies are targeting a microaerophilic bacterium known as Helicobacter pylori. While up to 85% of people infected with H. pylori never experience complications, it has been linked to gastric ulcers, chronic gastritis, and stomach cancer.
The agreement will seek to develop IMX101, a multicomponent vaccine against the bacterium.
